title: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
abstract: The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase. Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukaemia, lung and breast cancer and neuroblastoma. SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS–ERK signalling pathway. It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways. Reduction of SHP2 activity suppresses tumour cell growth and is a potential target of cancer therapy. Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumour xenograft models. Together, these data demonstrate that pharmacological inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.
authors.forename: Ying-Nan P
authors.initials: YN
authors.lastname: Chen
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: LaMarche
authors.forename: Ho Man
authors.initials: HM
authors.lastname: Chan
authors.forename: Peter
authors.initials: P
authors.lastname: Fekkes
authors.forename: Jorge
authors.initials: J
authors.lastname: Garcia-Fortanet
authors.forename: Michael G
authors.initials: MG
authors.lastname: Acker
authors.forename: Brandon
authors.initials: B
authors.lastname: Antonakos
authors.forename: Christine Hiu-Tung
authors.initials: CH
authors.lastname: Chen
authors.forename: Zhouliang
authors.initials: Z
authors.lastname: Chen
authors.forename: Vesselina G
authors.initials: VG
authors.lastname: Cooke
authors.forename: Jason R
authors.initials: JR
authors.lastname: Dobson
authors.forename: Zhan
authors.initials: Z
authors.lastname: Deng
authors.forename: Feng
authors.initials: F
authors.lastname: Fei
authors.forename: Brant
authors.initials: B
authors.lastname: Firestone
authors.forename: Michelle
authors.initials: M
authors.lastname: Fodor
authors.forename: Cary
authors.initials: C
authors.lastname: Fridrich
authors.forename: Hui
authors.initials: H
authors.lastname: Gao
authors.forename: Denise
authors.initials: D
authors.lastname: Grunenfelder
authors.forename: Huai-Xiang
authors.initials: HX
authors.lastname: Hao
authors.forename: Jaison
authors.initials: J
authors.lastname: Jacob
authors.forename: Samuel
authors.initials: S
authors.lastname: Ho
authors.forename: Kathy
authors.initials: K
authors.lastname: Hsiao
authors.forename: Zhao B
authors.initials: ZB
authors.lastname: Kang
authors.forename: Rajesh
authors.initials: R
authors.lastname: Karki
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Kato
authors.forename: Jay
authors.initials: J
authors.lastname: Larrow
authors.forename: Laura R
authors.initials: LR
authors.lastname: La Bonte
authors.forename: Francois
authors.initials: F
authors.lastname: Lenoir
authors.forename: Gang
authors.initials: G
authors.lastname: Liu
authors.forename: Shumei
authors.initials: S
authors.lastname: Liu
authors.forename: Dyuti
authors.initials: D
authors.lastname: Majumdar
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Meyer
authors.forename: Mark
authors.initials: M
authors.lastname: Palermo
authors.forename: Lawrence
authors.initials: L
authors.lastname: Perez
authors.forename: Minying
authors.initials: M
authors.lastname: Pu
authors.forename: Edmund
authors.initials: E
authors.lastname: Price
authors.forename: Christopher
authors.initials: C
authors.lastname: Quinn
authors.forename: Subarna
authors.initials: S
authors.lastname: Shakya
authors.forename: Michael D
authors.initials: MD
authors.lastname: Shultz
authors.forename: Joanna
authors.initials: J
authors.lastname: Slisz
authors.forename: Kavitha
authors.initials: K
authors.lastname: Venkatesan
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Markus
authors.initials: M
authors.lastname: Warmuth
authors.forename: Sarah
authors.initials: S
authors.lastname: Williams
authors.forename: Guizhi
authors.initials: G
authors.lastname: Yang
authors.forename: Jing
authors.initials: J
authors.lastname: Yuan
authors.forename: Ji-Hu
authors.initials: JH
authors.lastname: Zhang
authors.forename: Ping
authors.initials: P
authors.lastname: Zhu
authors.forename: Timothy
authors.initials: T
authors.lastname: Ramsey
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Keen
authors.forename: William R
authors.initials: WR
authors.lastname: Sellers
authors.forename: Travis
authors.initials: T
authors.lastname: Stams
authors.forename: Pascal D
authors.initials: PD
authors.lastname: Fortin
mesh_terms: D000494:Allosteric Regulation / Q000187:drug effects; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D020935:MAP Kinase Signaling System / Q000187:drug effects; D051379:Mice; D008819:Mice, Nude; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D015689:Oncogene Protein p21(ras) / Q000378:metabolism; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D055550:Protein Stability / Q000187:drug effects; D017434:Protein Structure, Tertiary / Q000187:drug effects; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D015203:Reproducibility of Results; D023041:Xenograft Model Antitumor Assays
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C000609471:SHP099; D020794:Receptor Protein-Tyrosine Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11; D015689:Oncogene Protein p21(ras)